NeuroPace, Inc., a medical device company focused on improving the lives of individuals with epilepsy, has announced that an abstract from its Post-approval Study of the RNS System will be presented ...
MOUNTAIN VIEW, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- December 4, 2024 – NeuroPace, Inc. (NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today ...
MOUNTAIN VIEW, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced three-year ...
First of its kind, multi-year collaboration leverages RNS System’s data to track responses of implanted RNS System patients enrolled in a biotechnology company’s clinical trial In strategic data ...
NeuroPace, Inc. (Nasdaq: NPCE), a medical technology company focused on transforming the lives of people living with epilepsy, today announced favorable Medicare reimbursement updates for the RNS ® ...
The RNS System Post-Approval Study (PAS) is the largest prospective post-approval study in neuromodulation for patients with drug-resistant focal epilepsy MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE ...
NPCE enters 2026 with rising RNS adoption, stronger margins and Medicare payment hikes that could boost hospital economics for replacement procedures.
MOUNTAIN VIEW, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, ...
MOUNTAIN VIEW, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results